Search clinical trials for: rituximab treatment

Total 65318 results

Washington University School of Medicine

Completed

Assessment and Management of Chronic Dyspepsia in Eastern Uganda

Dyspepsia | Helicobacter Pylori Infection

United States
The Lymphoma Academic Research Organisation
CHU de Nancy

Completed

Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

DLBCL

France, Belgium
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Withdrawn

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Burkitt Lymphoma | Refractory Burkitt... and other conditions

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma | Rituximab | Toripalimab

China
Assistance Publique - Hôpitaux de Paris

Unknown

Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU (EXCHANGE-IPF)

Exacerbation of Idiopathic Pulmonary Fibrosis

France
Boston Children's Hospital
Terrana ITP Research Fund

Completed

ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP (ICON1)

Immune Thrombocytopenia

United States, Canada
Mabion SA

Completed

MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Serbia, Poland, Bosnia and Herzegovina, Georgia, Ukraine
PETHEMA Foundation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea; GELCAB

Completed

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Lymphoma

Spain
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Leukemia

United States, Canada
NCIC Clinical Trials Group

Completed

Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma (IDEC-C2B8)

Lymphoma

Canada
Medical College of Wisconsin

Withdrawn

Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency

Granulomatous and Lymphocytic Interstitial Lung Disease
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia (RITUX PLUS)

Immune Thrombocytopenia

France
Mayo Clinic
University Health Network, Toronto; National Institute of Diabetes and Digestive... and other collaborators

Completed

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

Primary Focal Segmental Glomerulosclerosis

Canada, United States
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
University of Washington
National Cancer Institute (NCI)

Terminated

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom Macroglobulinemia

United States
Genentech, Inc.
Roche Pharma AG

Completed

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

Non-Hodgkin's Lymphoma

United States, Spain, France, Canada, United Kingdom, Austria, Belgium, Czechia, Russian Federation, Italy, Switzerland, Germany, Netherlands, Sweden
M.D. Anderson Cancer Center
Celgene; Onyx Therapeutics, Inc.

Terminated

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Lymphoma

United States
mAbxience Research S.L.
Laboratorio Elea Phoenix S.A.; Libbs Farmacêutica LTDA; Innogene Kalbiotech Pte... and other collaborators

Completed

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

Diffuse Large B-cell Lymphoma

Malaysia, Argentina, Colombia, India, South Africa, Philippines, Brazil, Russian Federation, Indonesia, Iran, Islamic Republic of, Mexico, Paraguay
Royal Marsden NHS Foundation Trust
Celgene Corporation

Active, not recruiting

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) (LEGEND)

Diffuse Large B-Cell Lymphoma

United Kingdom
Mayo Clinic
Celgene Corporation

Completed

Treatment of IgG4-Related Disease With Revlimid and Rituximab (TIGR2)

IgG4-related Disease | Retroperitoneal Fibrosis | Autoimmune Pancreatitis | IgG4-related Sclerosing Cholangitis | Immunoglobulin G Subclass 4 Related Disease

United States
Pfizer

Completed

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Follicular Lymphoma

United States, Spain, United Kingdom, Korea, Republic of, France, Portugal, India, Mexico, Switzerland, Japan, Germany, Romania, Greece, Austria, Belgium, Italy, Thailand, Croatia, Philippines, Russian Federation, Puerto Rico, Ukr... and more
Azienda Socio Sanitaria Territoriale degli Spedali...
University of Pisa; Azienda Ospedaliera Universitaria Policlinico; IRCCS Azienda... and other collaborators

Unknown

Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO)

Glomerulonephritis, Membranous

Italy
Seagen Inc.

Terminated

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma, Grade 3b | Lymphoma, B-cell | Lymphoma, Follicular, Grade 3b

United States
Swiss Group for Clinical Cancer Research

Completed

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Lymphoma

Switzerland
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
Seagen Inc.

Terminated

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Diffuse, Large B-Cell, Lymphoma | Follicular Lymphoma, Grade 3b | Transformed Lymphoma / DLBCL

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Spain
Nordic Nanovector

Withdrawn

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Non-Hodgkin Lymphoma

Germany
Pfizer
UCB Pharma

Terminated

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Lymphoma, Non-Hodgkin

Canada, United States, Spain, France, Singapore, Taiwan, Japan, Ireland, Belgium, United Kingdom, Germany, Slovakia, Thailand, Croatia, Czechia, Russian Federation, India, Sweden, Poland, Bulgaria, Hungary, Lithuania, Mexico, Puerto Rico and more
The First Affiliated Hospital with Nanjing Medical...

Unknown

Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Hoffmann-La Roche

Completed

MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

Lymphoma, Non Hodgkin

Spain
Hoffmann-La Roche

Completed

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Italy, United Kingdom, Belgium, Brazil, Denmark, France, Peru, Colombia, Canada, Georgia, Singapore, Spain, Thailand, Australia, Germany, Mexico, Russian Federation, South Africa, Finland, Bosnia and Herzegovina, Bulgaria, Croatia, ... and more
Xinhua Hospital, Shanghai Jiao Tong University...

Unknown

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor

Lymphoma | Acute Myeloid Leukemia | Neuroblastoma | Retinoblastoma | Hepatoblastoma | Acute Lymphoid Leukemia

China
Seagen Inc.

Terminated

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Follicular B-cell Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma Refractory

United States, Italy, Spain, United Kingdom, Czechia, Poland, France
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

Lymphoma, Follicular

Spain, Belgium, Czechia, France, Croatia, Germany, Austria, New Zealand, Australia, Greece, Hungary, Poland, Russian Federation
Mundipharma Research Limited

Terminated

A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab. (ROBIN)

Indolent B-cell NHL

Australia, Slovakia
Javeriana University
Universidad Nacional de Colombia

Completed

Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication

Therapy | H.Pylori Infection | CYP2C19 Polymorphism
Radboud University Medical Center

Unknown

Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome

Focal Segmental Glomerulosclerosis | Minimal Change Disease | Idiopathic Nephrotic Syndrome

Netherlands
Lymphoma Study Association
Association pour le Développement de la Recherche Clinique et Informatique...

Completed

Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

B Cell Lymphoma

France
Hoffmann-La Roche

Completed

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic

Belarus, Poland
University of South Florida

Completed

A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.

Rheumatoid Arthritis

United States
Seagen Inc.

Terminated

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Lymphoma, Large B-cell, Diffuse | Lymphoma, B-cell

United States, Spain, Italy, Czechia, Poland
University Hospital, Rouen

Unknown

Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study) (CREHA)

Acquired Haemophilia

France
Mingzhi Zhang

Unknown

Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy Study of Two Treatments in the Remission of Vasculitis (MAINRITSAN)

Microscopic Polyangiitis | Wegener Granulomatosis

France
Hospital de Clinicas de Porto Alegre
Aché Laboratórios Farmacêuticos Ltda

Completed

Helicobacter Eradication Relief of Dyspeptic Symptoms (HEROES-12)

Functional Dyspepsia

Brazil
University Hospital, Tours
Roche Pharma AG

Completed

Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation (RITUX-ERAH)

Humoral Rejection in Kidney Transplantation

France
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Australia, Brazil, Canada, Mexico, New Zealand, Peru

Search clinical trials for: rituximab treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations